drugset / Trial / NCT06240754
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
Phase 2
Recruiting
15 enrolled
Washington University School of Medicine
Bristol-Myers Squibb · collabDamon Runyon Cancer Research Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2028-01-31
- Completion
- 2029-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enasidenib | Small molecule | 100 mg | — |